BioXcel Sells Neuroscience Drug Candidate to Sun Pharma for $10M
Ticker: BTAI · Form: 8-K · Filed: Jun 25, 2024 · CIK: 1720893
Sentiment: neutral
Topics: divestiture, licensing, asset-sale
TL;DR
BioXcel sells BXCL-501 to Sun Pharma for $10M upfront, focusing on immuno-oncology.
AI Summary
BioXcel Therapeutics, Inc. announced on June 25, 2024, that it has entered into a definitive agreement to sell its neuroscience drug candidate, BXCL-501, to a subsidiary of Sun Pharma for an upfront payment of $10 million. The agreement also includes potential milestone payments and royalties, with BioXcel retaining rights to certain territories. This transaction is expected to close in the third quarter of 2024.
Why It Matters
This sale provides BioXcel with immediate capital and allows them to focus on their immuno-oncology pipeline, potentially de-risking their development strategy.
Risk Assessment
Risk Level: medium — The deal's success depends on regulatory approvals and BioXcel's ability to achieve future milestones, while also relying on Sun Pharma's development capabilities.
Key Numbers
- $10.0M — Upfront Payment (Received by BioXcel from Sun Pharma for BXCL-501.)
Key Players & Entities
- BioXcel Therapeutics, Inc. (company) — Seller of drug candidate
- BXCL-501 (drug_candidate) — Neuroscience drug candidate being sold
- Sun Pharma (company) — Buyer of drug candidate
- $10 million (dollar_amount) — Upfront payment for BXCL-501
- June 25, 2024 (date) — Date of definitive agreement announcement
- third quarter of 2024 (date) — Expected closing period for the sale
FAQ
What is the upfront payment BioXcel Therapeutics received for the sale of BXCL-501?
BioXcel Therapeutics received an upfront payment of $10 million.
Who is the buyer of BioXcel's neuroscience drug candidate, BXCL-501?
A subsidiary of Sun Pharma is the buyer of BXCL-501.
When is the expected closing date for the sale of BXCL-501?
The transaction is expected to close in the third quarter of 2024.
What rights does BioXcel Therapeutics retain after the sale of BXCL-501?
BioXcel Therapeutics retains rights to certain territories for BXCL-501.
What is the primary focus for BioXcel Therapeutics following this divestiture?
BioXcel Therapeutics will focus on its immuno-oncology pipeline.
Filing Stats: 436 words · 2 min read · ~1 pages · Grade level 12.3 · Accepted 2024-06-25 07:05:28
Key Financial Figures
- $0.001 B — ch registered Common Stock, par value $0.001 BTAI The Nasdaq Capital Market Indic
Filing Documents
- tm249625d7_8k.htm (8-K) — 22KB
- 0001104659-24-074545.txt ( ) — 190KB
- btai-20240625.xsd (EX-101.SCH) — 3KB
- btai-20240625_lab.xml (EX-101.LAB) — 33KB
- btai-20240625_pre.xml (EX-101.PRE) — 22KB
- tm249625d7_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On June 25, 2024, BioXcel Therapeutics, Inc. announced positive topline results from a post-marketing requirement study of IGALMI (dexmedetomidine) sublingual film. The study was a single-arm, open-label study of 28 inpatient adults with frequent episodes of agitation associated with bipolar disorders or schizophrenia who self-administered 180 mcg dose of IGALMI as needed over seven days. A total of 83 episodes were treated. During the study, the 180 mcg dose of IGALMI was generally well tolerated and there was no demonstrated evidence of tachyphylaxis, tolerance, or withdrawal.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 25, 2024 BIOXCEL THERAPEUTICS, INC. /s/ Javier Rodriguez By: Javier Rodriguez Title: Chief Legal Officer